Investigating the role of 3' tsRNAs in treating diseases like cancer
Official title: 3' tsRNAs: biologic function and pre-clinical targeting for treating human disease
Funded at Stanford University · NIH-10884932 · Data updated 2026-11-12
This study is looking at a special type of tiny RNA that might help heal tissues and fight cancer, and it aims to see if using a specific treatment can slow down cancer growth and support healthy cells, which could lead to better therapies for people with liver cancer and similar conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | July 8, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $518,152 |
| NIH project number | 5R01CA277059-02 |
| Project ID | NIH-10884932 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with liver cancer or other conditions characterized by abnormal cell proliferation.
✕Less likely to help
Patients with non-cancerous conditions or those not experiencing issues related to cell proliferation may not benefit from this research.
What this research studies
This research focuses on a specific type of small RNA called 3' tsRNAs, which are believed to play a crucial role in tissue regeneration and cancer. The team aims to explore how targeting these tsRNAs with antisense oligonucleotides can inhibit cancer cell growth and promote healthy cell function. By studying the interactions between 3' tsRNAs and messenger RNAs, the researchers hope to develop new gene therapies that could improve treatment outcomes for patients with liver cancer and other hyperproliferative conditions. The approach involves both laboratory studies and potential pre-clinical applications in animal models.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that effectively treat liver cancer and enhance tissue regeneration.
How similar studies have gone: While the specific targeting of 3' tsRNAs is a relatively novel approach, previous research has shown promise in manipulating small RNAs for therapeutic purposes.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Kay, Mark a — Stanford University
- Study coordinator: Kay, Mark a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.